ClinicalTrials.gov
ClinicalTrials.gov Menu

Hybrid Imaging Modalities for the Evaluation of Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00230152
Recruitment Status : Completed
First Posted : September 30, 2005
Last Update Posted : October 22, 2010
Sponsor:
Information provided by:
Rambam Health Care Campus

Brief Summary:

The synergistic value of the fusion of physiologic and anatomical data has been described using several co-registration techniques for various nuclear medicine procedures and morphologic imaging modalities (single photon emission computed tomography-computed tomography [SPECT-CT], SPECT-magnetic resonance imaging [MRI], camera-based positron emission tomography [PET]-CT and PET-CT). The researchers hypothesize that fusion of nuclear medicine (NM) and CT data acquired sequentially in a single imaging session on one device is clinically superior to side-by-side evaluation of separately performed imaging tests. They hypothesize that more accurate localization of increased radiotracer activity on NM procedures will improve the diagnostic accuracy for detection of infection and will subsequently have a significant impact on patient management.

The purpose of the present study is to assess the clinical value of this new technology of fused imaging in patients undergoing diagnostic nuclear medicine evaluation for suspicion of an infection process.


Condition or disease Intervention/treatment Phase
Infectious Diseases Device: Imaging Not Applicable

Detailed Description:

The researchers hypothesize that fusion of nuclear medicine (NM) and CT data acquired sequentially in a single imaging session on one device is clinically superior to side-by-side evaluation of separately performed imaging tests. They hypothesize that more accurate localization of increased radiotracer activity on NM procedures will improve the diagnostic accuracy for detection of infection and will subsequently have a significant impact on patient management.

The purpose of the present study is to assess the clinical value of this new technology of fused imaging in patients undergoing diagnostic nuclear medicine evaluation for suspicion of an infection process.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 300 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Nuclear Medicine for the Evaluation of Infection-the Added Value of Hybrid Imaging Modalities
Study Start Date : February 2006
Actual Primary Completion Date : April 2007
Actual Study Completion Date : March 2009

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. The impact of the imaging modality on patient management [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. The impact of the imaging modality on patient management [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients referred for NM imaging procedures to assess the presence of infectious processes.
  • Patients signed informed consent

Exclusion Criteria:

  • The study will not be performed in pregnant or lactating women.
  • Patients unable or unwilling to tolerate the scan until its completion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00230152


Locations
Israel
Rambam Medical Center
Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Zohar Keidar, MD, PhD Rambam Health Care Campus

Responsible Party: Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT00230152     History of Changes
Other Study ID Numbers: infectionCTIL
First Posted: September 30, 2005    Key Record Dates
Last Update Posted: October 22, 2010
Last Verified: September 2005

Additional relevant MeSH terms:
Communicable Diseases
Infection